Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to
receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily,
and will be treated for 24 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Collaborator:
Ministry of Health of Russian Federation
Treatments:
Enalapril Enalaprilat LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan